Setting evidence-based priorities for diabetes care improvement

International Journal for Quality in Health Care

Volumn 15, Issue 4, 2003, Pages 283-285

  O'Connor, Patrick J ^a  

^a HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C;

BLOOD PRESSURE REGULATION; DIABETES CONTROL; DIABETES MELLITUS; DISEASE CONTROL; DYSLIPIDEMIA; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL INFORMATION; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SMOKING CESSATION; STROKE; VASCULAR DISEASE;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; QUALITY ASSURANCE, HEALTH CARE;

EID: 0042023670     PISSN: 13534505     EISSN: None     Source Type: Journal    
DOI: 10.1093/intqhc/mzg062     Document Type: Editorial

References (26)

1. Stepien CJ, Bowbeer MA, Hiss RG. Screening for diabetic retinopathy in communities. Diabetes Educ 1992; 18: 115-120.
2. Hiss RG, Stepien CJ, Bowbeer MA. Community-based retinopathy clinics. Diabetes Care 1992; 15: 144-145.
3. Sperl-Hillen J, O'Connor PJ, Carlson RR et al. Improving diabetes care in a large health care system: an enhanced primary care approach. Jt Comm J Qual Improv 2000; 26: 615-622.
4. O'Connor PJ, Sperl-Hillen JM, Pronk NP, Murray T. Primary care clinic-based chronic disease care. Dis Manage Health Outcomes 2001; 9: 691-698.
5. O'Connor PJ, Bishop D, Solberg LI, Desai J, Crain AL, Rush W, Sperl-Hillen JM, Mode N, Duncan J. Improved diabetes care in Minnesota medical groups, 1995-2001. Diabetes 2003; 52(suppl. 1): A267.
6. Barrett-Connor E, Wingard DL. 'Normal' blood glucose and coronary risk. BMJ 2001; 322: 5-6.
7. Nyman MA, Murphy ME, Schryver PG, Naessens JM, Smith SA. Improving performance in diabetes care: a multicomponent intervention. Eff Clin Pract 2000; 3: 205-212.
8. Sidorov J, Gabbay R, Harris R et al. Disease management for diabetes mellitus: impact on Hemoglobin A1c. Am J Manag Care 2000; 6: 1217-1226.
9. Sutherland JE, Hoehns JD, O'Donnell B, Wiblin RT. Diabetes management quality improvement in a family practice residency program. J Am Board Fam Pract 2001; 14: 243-251.
10. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J. Med 1993; 329: 977-986.
11. O'Connor PJ, Spann SJ, Woolf SH. Care of type 2 diabetes mellitus: a review of the evidence. J Fam Pract 1998; 47 (suppl. 5): S13-S22.
12. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
13. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999; 159: 1873-1880.
14. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997; 20: 1847-1853.
15. UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
16. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
17. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. J Am Med Assoc 2002; 287: 2542-2551.
18. Barton S, ed. Clinical Evidence Concise: The International Source of the Best Available Evidence for Effective Health Care, 7th edition. Kingsport, TN: BMJ Publishing Group, 2002.
19. Kendall DM, Bergenstal RM. Comprehensive management of patients with Type 2 diabetes: Establishing priorities of care. Am J Managed Care 2001; 7(suppl): S327-S343.
20. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-872.
21. Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care 1997; 20: 469-471.
22. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. J Am Med Assoc 1992; 268: 1292-1300.
23. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
24. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
25. Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
26. ALLHAT Investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002; 288: 2981-2997.